ABCDEFGHIJKLMNOPQRSTUVWXYZAAABAC
1
Company/MetricLabCorpQuestOPKO HealthEnzo Biochem
2
In USD MillionsAs a % of RevenueNotesIn USD MillionsAs a % of RevenueNotesIn USD MillionsAs a % of RevenueNotesIn USD MillionsAs a % of RevenueNotes
3
Revenue9,253.40LabCorp Diagnostics segment revenue was 65% of the total revenue generated by the company. 9,437.001,262.24The data provided is for the Diagnostics segment of OPKO Health, which includes Bio-Reference Laboratories, 4Kscore Test, and Point-of-Care Diagnostics. 47.96Clinical laboratory services revenue was 63% of total revenue of Enzo Biochem.
4
Operating Income2,634.9028.5%1,425.0015.10%138.9211.01%(14.64)-30.52%
5
EBITDA2,466.7526.66%The EBITDA for the Diagnostics segment was estimated using the percentage share of the diagnostics segment's revenue. That is 65% of the entire company's EBITDA. 2,466.0026.13%N/AN/AThe EBITDA for OPKO Diagnostcs segment was not provided. (14.65)-30.54%
6
SG&A1,110.2012.00%The SG&A for the Diagnostics segment was estimated using the percentage share of the diagnostics segment's revenue. That is 65% of the entire company's SG&A expenses. 1,509.0015.99%266.4921.11%23.5349.06%
7
Cost of Sales6,045.6565.33%The Cost of Sales for the Diagnostics segment was estimated using the percentage share of the diagnostics segment's revenue. That is 65% of the entire company's Cost of Sales. 5,823.0061.70%823.9365.27%38.9081.10%
8
Gross Margin3,207.7534.67%Gross profit was calculated by subtracting the Cost of Sales from the Revenue of the Diagnostics department. 3,614.0038.30%438.3234.73%Gross profit was calculated by subtracting the Cost of Sales from the Revenue of the Diagnostics department. 9.0619%Gross profit was calculated by subtracting the Cost of Sales from the Revenue of the Diagnostics department.
9
Price per encounter or by accessionN/AN/AN/AN/AN/AN/AN/AN/A
10
Bad Debt RatioN/AN/AN/AN/AN/AN/AN/AN/A
11
Days Sales OutstandingN/AN/ARecivables turnover 5.54N/A46 daysN/AN/AN/AN/A
12
Sources
https://ir.labcorp.com/static-files/3d9cc784-f746-461c-97eb-fb364031a491
https://www.wsj.com/market-data/quotes/LH/financials/annual/income-statement
https://ir.labcorp.com/fundamentals/ratios

https://sec.report/Document/0001022079-21-000029/
https://www.wsj.com/market-data/quotes/DGX/financials/annual/income-statement
https://www.opko.com/investors/sec-filings/all-sec-filings/content/0000944809-21-000015/0000944809-21-000015.pdf
https://ir.enzo.com/sec-filings/annual-reports/content/0001213900-20-032066/0001213900-20-032066.pdf
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100